PMID- 31834862
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20201123
IS  - 2191-0251 (Electronic)
IS  - 0334-018X (Linking)
VI  - 33
IP  - 2
DP  - 2020 Feb 25
TI  - Comparison between metabolically healthy obesity and metabolically unhealthy 
      obesity by different definitions among Mexican children.
PG  - 215-222
LID - 10.1515/jpem-2019-0077 [doi]
AB  - Background There is no consensus on the definition of metabolically healthy 
      obesity (MHO) and the diagnostic criteria in children. Objectives To estimate the 
      prevalence of MHO and compare clinical and biochemical characteristics between 
      MHO and metabolically unhealthy obesity (MUO), and to evaluate the association 
      between MUO and cardiovascular disease (CVD) risk, anthropometrics and family 
      background using different definitions in children. Methods This was a 
      cross-sectional study. Participants included 224 obese children between the years 
      2007 and 2017. MHO was defined by three different criteria: (i) absence of 
      metabolic syndrome (MHO-MS), (ii) no insulin resistance (IR) by homeostatic model 
      assessment (HOMA) <3.16 cut-off (MHO-IR3.16) and (iii) absence of IR at <95th 
      percentile for Mexican children (MHO-95th). Results The prevalence of MHO-MS, 
      MHO-IR3.16 and MHO-IR95th was 12.9%, 56.3% and 41.5%, respectively. The 
      prevalence of simultaneous MHO-MS plus MHO-IR95th was 5.36%. Children with MHO-MS 
      vs. MUO-MS showed lower height, weight and body mass index (BMI) percentiles; 
      MHO-IR3.16 vs. MUO-IR3.16 showed lower age, acanthosis, Tanner, waist 
      circumference (WC), waist-to-height ratio (WHtR), systolic blood pressure (SBP), 
      diastolic blood pressure (DBP) and glucose; and MHO-IR95th vs. MUO-IR95th showed 
      lower acanthosis, WC, DBP, glucose and high high-density lipoprotein cholesterol 
      (HDL-C). MUO-MS was associated with WC > 90th, type 2 diabetes mellitus (T2DM) in 
      first-degree relatives and obesity in siblings. MUO-IR3.16 was associated with 
      pubertal stages, WC > 90th, WHtR > 0.55 and fasting hyperglycemia. MUO-IR95th was 
      associated with WHtR > 0.55 and HDL < 10th. MHO-MS and MHO-IR3.16 or MHO-IR95th 
      did not have agreement. Conclusions The prevalence of MHO varied depending on the 
      definition, although the real MHO with no MS or IR is very low. Low DBP and high 
      HDL-C in MHO were present in any definition. Association of MUO with 
      anthropometric, biochemical and family background differs across definitions.
FAU - Evia-Viscarra, Maria Lola
AU  - Evia-Viscarra ML
AUID- ORCID: 0000-0002-2916-3108
AD  - Pediatrics Endocrinology, Diabetes in Child and Adolescent, Postgrade, MSc in 
      Clinical Investigation, Department of Pediatric Endocrinology, Hospital Regional 
      de Alta Especialidad del Bajio, Blvd. Milenio 130, San Carlos la Roncha, C.P. 
      37670, Leon, Guanajuato, Mexico.
FAU - Guardado-Mendoza, Rodolfo
AU  - Guardado-Mendoza R
AD  - Department of Research, Hospital Regional de Alta Especialidad del Bajio, Leon, 
      Guanajuato, Mexico.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Germany
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
SB  - IM
MH  - Adolescent
MH  - *Body Mass Index
MH  - Child
MH  - Cross-Sectional Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Insulin Resistance
MH  - Male
MH  - Mexico/epidemiology
MH  - Obesity, Metabolically Benign/*epidemiology/*physiopathology
MH  - Pediatric Obesity/*epidemiology/*physiopathology
MH  - Prevalence
MH  - Prognosis
MH  - Risk Factors
MH  - *Waist Circumference
OTO - NOTNLM
OT  - insulin resistance
OT  - metabolic syndrome
OT  - metabolically healthy obesity
OT  - pediatric obesity
EDAT- 2019/12/14 06:00
MHDA- 2020/11/24 06:00
CRDT- 2019/12/14 06:00
PHST- 2019/02/11 00:00 [received]
PHST- 2019/10/07 00:00 [accepted]
PHST- 2019/12/14 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2019/12/14 06:00 [entrez]
AID - /j/jpem.ahead-of-print/jpem-2019-0077/jpem-2019-0077.xml [pii]
AID - 10.1515/jpem-2019-0077 [doi]
PST - ppublish
SO  - J Pediatr Endocrinol Metab. 2020 Feb 25;33(2):215-222. doi: 
      10.1515/jpem-2019-0077.